Abstract
Nicotinamide Adenine Dinucleotide (NAD+) precursors, specifically Nicotinamide Riboside (NR), have shown significant potential in animal models for reversing obesity-related mitochondrial dysfunction. However, human clinical trials have yielded inconsistent results. This study, published by Lapatto et al., utilized a unique twin-study design to investigate the effects of long-term (5-month) NR supplementation. While NR successfully boosted cellular NAD+ levels, increased muscle mitochondrial biogenesis, and improved gut microbiota composition, these cellular improvements did not translate into systemic metabolic benefits such as weight loss or improved insulin sensitivity. These findings suggest a complex uncoupling between mitochondrial biogenesis and metabolic health in humans.
Introduction
Nicotinamide Adenine Dinucleotide (NAD+) is a fundamental coenzyme required for energy metabolism and DNA repair. Levels of NAD+ naturally decline with age and obesity, leading to mitochondrial dysfunction. While boosting NAD+ with precursors like NR has been highly effective in mice, human trials have often been too short-term to show definitive results. This research addresses this gap by examining the effects of a five-month escalating dose of NR in a cohort of monozygotic twins, providing a controlled look at how genetics and environment interact with NAD+ supplementation.
Study Design and Methodology
The researchers recruited 22 pairs of monozygotic (identical) twins who were discordant for BMI—meaning one twin was lean while the other was heavier. This design is particularly powerful because it controls for genetic background while allowing researchers to see if baseline obesity affects the response to NR.
Participants received an escalating dose of NR, starting at 250 mg/day and reaching 1000 mg/day for the final four months. The study employed a comprehensive multi-omics approach, including:
- Targeted Metabolomics: Tracking NAD+ metabolites in the blood.
- Tissue Biopsies: Analyzing muscle and white adipose tissue (WAT) via Transmission Electron Microscopy (TEM) and qPCR.
- Epigenetics: Measuring DNA methylation using the Infinium MethylationEPIC array.
- Microbiome Analysis: 16S rRNA sequencing of fecal samples.
- Functional Assays: Testing the differentiation capacity of primary myoblasts (muscle stem cells).
Key Findings
1. Robust NAD+ Elevation and Mitochondrial Biogenesis
NR supplementation successfully increased whole-blood NAD+ levels by 2.3-fold. Crucially, this study provided the first clear evidence in humans that NR increases the physical number of mitochondria in muscle tissue (by approximately 14%) and boosts muscle mitochondrial DNA (mtDNA) by 30%. This occurred regardless of the participant's initial BMI, suggesting that NR is a potent stimulator of mitochondrial biogenesis across different metabolic profiles.
2. Stem Cell Differentiation and Epigenetic Remodeling
The study observed a significant shift in muscle stem cell behavior. NR reduced the number of PAX7+ satellite cells (muscle stem cells) but increased their differentiation, suggesting that NR encourages these cells to fuse with and repair existing muscle fibers. Furthermore, NR acted as an epigenetic modifier, reducing global DNA methylation in muscle. Specifically, it targeted genes like PGC-1α, the master regulator of mitochondrial biogenesis, effectively "priming" the tissue for enhanced energy production.
3. Gut Microbiota Improvements
Beyond internal tissues, NR influenced the gut environment. Supplementation increased the abundance of Faecalibacterium prausnitzii, a beneficial bacterium known for its anti-inflammatory properties and positive associations with metabolic health. This suggests that the benefits of NAD+ precursors may be partially mediated through the gut-muscle axis.
The Metabolic Paradox
Despite the clear improvements at the cellular and microbial levels, the study encountered a "metabolic paradox." The participants did not experience weight loss or improved insulin sensitivity. In fact, across the cohort, there was a slight increase in body weight (approximately 3kg) and a minor decrease in insulin sensitivity.
This discrepancy suggests that simply increasing mitochondrial number is not a "silver bullet" for metabolic syndrome in humans. The weight gain observed may have been seasonal or a result of the open-label study design, potentially masking the metabolic benefits that NR might provide in a more controlled caloric environment.
Conclusion and Future Directions
The Lapatto et al. study confirms that NR is a safe and effective tool for boosting NAD+ and mitochondrial biogenesis in humans over the long term. However, the lack of systemic metabolic improvement highlights the complexity of human energy regulation compared to animal models.
Future research should focus on populations where mitochondrial dysfunction is a primary driver of disease, such as individuals with primary mitochondrial myopathies or age-related sarcopenia, rather than using NR as a general weight-loss supplement. Additionally, further investigation into the epigenetic "priming" caused by NR could reveal long-term benefits that were not captured within the five-month window of this trial.
Summary updated